Aarti Pharmalabs Limited (NSE:AARTIPHARM)

Market Cap	58.23B -16.1%
Revenue (ttm)	18.19B -13.5%
Net Income	1.75B -35.9%
EPS	19.25 -35.9%
Shares Out	90.66M
PE Ratio	33.37
Forward PE	36.09
Dividend	3.50 (0.55%)
Ex-Dividend Date	Feb 16, 2026

Volume	199,732
Open	635.00
Previous Close	633.25
Day's Range	635.00 - 659.70
52-Week Range	585.00 - 971.00
Beta	0.40
Analysts	n/a
Price Target	n/a
Earnings Date	May 25, 2026

About Aarti Pharmalabs

Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides con...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2019
• Employees: 2,162
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: AARTIPHARM

Financial Performance

In fiscal year 2026, Aarti Pharmalabs's revenue was 18.29 billion, a decrease of -13.52% compared to the previous year's 21.15 billion. Earnings were 1.75 billion, a decrease of -35.86%.